59c50e1e-fc77-441e-93c2-f69c013f362c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.400
- ANGIOGENESIS+0.300
- E2F_TARGETS+0.300
- MITOTIC_SPINDLE+0.200
- MYC_TARGETS_V2+0.200
- PANCREAS_BETA_CELLS+0.200
- PROTEIN_SECRETION+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- APICAL_SURFACE-0.400
- BILE_ACID_METABOLISM-0.300
- CHOLESTEROL_HOMEOSTASIS-0.300
- COMPLEMENT-0.300
- ESTROGEN_RESPONSE_EARLY-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- HEME_METABOLISM-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.893 |
| 2 | 25f272b8-11f5-4edc-9c54-f4115fc0a5de | — | — | 0.883 |
| 3 | 0edf46a2-3dfb-4bae-b642-281e05975bd1 | — | — | 0.882 |
| 4 | 2bd9ef82-12dc-4dcb-8a2c-c58cdf463116 | — | — | 0.873 |
| 5 | 32a88c36-6b9a-483f-ad00-bf899ae279ba | — | — | 0.855 |
| 6 | SAMN03290918 | — | — | 0.852 |
| 7 | SAMN03290896 | — | — | 0.841 |
| 8 | BS_1AYRM596 | medulloblastoma | — | 0.841 |
| 9 | SRR11296878 | — | — | 0.837 |
| 10 | f2c3b90a.7e75.4a2a.925e.29eb9a2acac2 | — | cohortA3 | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |